# US 2005/0238740 A1 · Use of mastic and its components for the control of microbial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0238740 A1
- Document ID: US20050238740A1
- Status: Published application
- Kind: A1
- Application number: 10/512,963
- Filed: 2003-05-01
- Published: 2005-10-27
- Earliest claimed: 2002-05-01
- Inventors: Spiros Fotinos; Ligia Panaitescu; Dimitris Kletsas; Harris Platsinis; Irene Zervolea; Alexios Skaltsounis; Sofia Mitakou; Prokopios Magiatis
- Web page: https://patentgrep.com/patent/US20050238740A1

## CPC

- A61K 36/22: Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical formulations and methods of manufacture of such formulations used in the treatment of microbial infections and cell proliferation conditions. The pharmaceutical formulations include anti-microbial and/or anti-cell proliferation agents which comprise a mastic extract product and essential oil, or a mastic isolated component, or synthetic equivalents thereof prepared as oral or topical formulations. Further, methods of treating microbial infections or cell proliferation conditions in a subject are provided wherein an oral or topical formulation of an anti-microbial agent or anti-cell proliferation agent is administered to a subject so as to treat infection or condition.

## Claims

### Claim 1

A pharmaceutical formulation for orally or topically delivering to a subject an anti-microbial agent, wherein the anti-microbial agent comprises:
a therapeutically effective amount of a mastic extract product and essential oil isolated from the species Pistacia lentiscus var. chia or a synthetic equivalent thereof; and wherein the mastic product and essential oil are formulated for oral or topical administration.

### Claim 2 (depends on 1)

A pharmaceutical formulation according to claim 1, wherein the anti-microbial agent is selected from the group consisting of an anti-H. pylori agent, an anti-Propionibacterium agent, an anti-Staphylococcus agent, and an anti-Pseudomonas agent.

### Claim 3 (depends on 2)

A pharmaceutical formulation according to claim 2, wherein the mastic extract product is a mastic whole extract product.

### Claim 4 (depends on 2)

A pharmaceutical formulation according to claim 2, wherein the mastic extract product is a mastic acid extract product.

### Claim 5 (depends on 2)

A pharmaceutical formulation according to claim 2, wherein the mastic extract product is a mastic neutral extract product.

### Claim 6

A pharmaceutical formulation for orally of topically delivering to a subject an anti-microbial agent, wherein the anti-microbial agent comprises:
a therapeutically effective amount of a mastic isolated component isolated from the species Pistacia lentiscus var. chia or a synthetic equivalent thereof; and wherein the mastic isolated component is formulated for oral or topical administration.

### Claim 7 (depends on 6)

A pharmaceutical formulation according to claim 6, wherein the mastic isolated component is an isolated component from a mastic whole extract, acid extract, neutral extract, or essential oil.

### Claim 8 (depends on 7)

A pharmaceutical formulation according to claim 7, wherein the mastic isolated component is selected from the group consisting of masticadienonic acid, aldehyde or alcohol; masticadienolic acid, aldehyde or alcohol; isomasticadienonic acid, aldehyde or alcohol; isomasticadienolic acid, aldehyde or alcohol; oleanolic acid, aldehyde or alcohol; oleanonic acid, aldehyde or alcohol; α-pinene; β-myrcene; tirucallol; and betulonal.

### Claim 9 (depends on 8)

A pharmaceutical formulation according to claim 8, wherein the anti-microbial agent is selected from the group consisting of an anti-H. pylori agent, an anti-Propionibacterium agent, an anti-Staphylococcus agent, and an anti-Pseudomonas agent.

### Claim 10

A pharmaceutical formulation for orally or topically delivering to a subject an anti-cell proliferation agent, wherein the anti-cell proliferation agent comprises:
a therapeutically effective amount of an anti-cell proliferation agent comprising essential oil isolated from the species Pistacia lentiscus var. chia or a synthetic equivalent thereof; and wherein the essential oil is formulated for oral or topical administration.

### Claim 11 (depends on 10)

A pharmaceutical formulation according to claim 10, wherein the anti-cell proliferation agent further comprises a mastic whole extract product.

### Claim 12 (depends on 10)

A pharmaceutical formulation according to claim 10, wherein the anti-cell proliferation agent further comprises a mastic acid extract product.

### Claim 13 (depends on 10)

A pharmaceutical formulation according to claim 10, wherein the anti-cell proliferation agent further comprises a mastic neutral extract product.

### Claim 14 (depends on 10)

A pharmaceutical formulation according to claim 10, wherein the anti-cell proliferation agent further comprises a mastic isolated component product.

### Claim 15

A method for treating H. pylori infection in a subject infected with H. pylori or at risk for H. pylori infection, the method comprising:
providing an anti-H. pylori agent comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof to the subject in an oral pharmaceutical formulation; and
orally administering an effective amount of the anti-H. pylori agent so as to treat the H. pylori infection in the subject.

### Claim 16 (depends on 15)

A method according to claim 15, wherein orally administering further comprises administering from 1 to 4 doses per day equivalent to about 1 to 5 g/day of a tablet formulation of the anti-H. pylori agent for up to about 6 months.

### Claim 17 (depends on 15)

A method according to claim 15, wherein the anti-H. pylori agent is a mastic whole extract product.

### Claim 18 (depends on 15)

A method according to claim 15, wherein the anti-H. pylori agent is a mastic acid extract product.

### Claim 19 (depends on 15)

A method according to claim 15, wherein the anti-H. pylori agent is a mastic neutral extract product.

### Claim 20 (depends on 15)

A method according to claim 15, wherein the anti-H. pylori agent is a mastic essential oil product.

### Claim 21 (depends on 15)

A method according to claim 15, wherein the anti-H. pylori agent is a mastic isolated component.

### Claim 22

A method for treating microbial infection in a subject infected with or at risk for one of Staphylococcus, Pseudomonas, or Propionibacterium infection, the method comprising:
providing an anti-microbial agent therapeutically effective against the one of Staphylococcus, Pseudomonas, or Propionibacterium infection comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof to the subject in a topical pharmaceutical formulation; and
topically administering an effective amount of the anti-microbial agent so as to treat the microbial infection in the subject.

### Claim 23 (depends on 22)

A method according to claim 22, wherein topically administering further comprises administering 1-4 applications of a gel or cream formulation per day for a range of about one-half month to 6 months.

### Claim 24 (depends on 22)

A method according to claim 22 wherein the anti-microbial agent is an anti-Staphylococcus agent.

### Claim 25 (depends on 22)

A method according to claim 22 wherein the anti-microbial agent is an anti-Pseudomonas agent.

### Claim 26 (depends on 22)

A method according to claim 22 wherein the anti-microbial agent is an anti-Propionibacterium agent.

### Claim 27 (depends on 26)

A method according to claim 26, wherein the anti-Propionibacterium acnes agent is a mastic whole extract product.

### Claim 28 (depends on 26)

A method according to claim 26, wherein the anti-Propionibacterium acnes agent is a mastic acid extract product.

### Claim 29 (depends on 26)

A method according to claim 26, wherein the anti-Propionibacterium acnes agent is a mastic neutral extract product.

### Claim 30 (depends on 26)

A method according to claim 26, wherein the anti-Propionibacterium acnes agent is a mastic essential oil product.

### Claim 31 (depends on 26)

A method according to claim 26, wherein the anti-Propionibacterium acnes agent is a mastic isolated component.

### Claim 32

A method for treating cell hyperproliferation in a subject clinically manifesting cell hyperproliferation or at risk for clinically manifesting cell hyperproliferation, the method comprising:
providing an anti-cell hyperproliferation agent comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof in an oral pharmaceutical formulation; and
orally administering an effective amount of the anti-cell hyperproliferation agent so as to treat cell hyperproliferation in the subject.

### Claim 33

A method for treating cell hyperproliferation in a subject clinically manifesting evidence of cell hyperproliferation, the method comprising:
providing an anti-cell hyperproliferation agent comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof in a topical pharmaceutical formulation; and
topically administering an effective amount of the anti-cell hyperproliferation agent so as to treat cell hyperproliferation in the subject.

### Claim 34 (depends on 33)

A method according to claim 33, wherein evidence of cell hyperproliferation comprises dandruff.

### Claim 35 (depends on 33)

A method according to claim 33, wherein topically administering further comprises administering the anti-cell hyperproliferation agent once or twice per day in a shampoo wherein the shampoo contains from about 1% to 25% anti-cell hyperproliferation agent.

### Claim 36 (depends on 33)

A method according to claim 33, wherein the anti-cell hyperproliferation agent is a mastic whole extract product.

### Claim 37 (depends on 33)

A method according to claim 33, wherein the anti-cell hyperproliferation agent is a mastic acid extract product.

### Claim 38 (depends on 33)

A method according to claim 33, wherein the anti-cell hyperproliferation agent is a mastic neutral extract product.

### Claim 39 (depends on 33)

A method according to claim 33, wherein the anti-cell hyperproliferation agent is a mastic essential oil product.

### Claim 40 (depends on 33)

A method according to claim 33, wherein the anti-cell hyperproliferation agent is a mastic isolated component product.

### Claim 41

A method of manufacturing a formulation of an anti-H. pylori agent wherein the method comprises:
adding an anti-H. pylori agent comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof to an oral pharmaceutical formulation; wherein
the oral formulation of the anti-H. pylori agent is used in the treatment of H. pylori infection.

### Claim 42

A method of manufacturing a formulation of an anti-Propionibacterium agent wherein the method comprises:
adding an anti-Propionibacterium agent comprising a mastic whole extract, acid extract, neutral extract, essential oil or isolated component product or synthetic equivalent thereof to a topical pharmaceutical formulation; wherein
the topical formulation of the anti-Propionibacterium agent is used in the treatment of Propionibacterium infection.

### Claim 43

A method of manufacturing a formulation of an anti-cell hyperproliferation agent wherein the method comprises:
adding an anti-cell hyperproliferation agent comprising a mastic whole extract, acid extract, neutral extract, essential oil of isolated component product of synthetic equivalent thereof to an oral or topical pharmaceutical formulation; wherein
the oral or topical pharmaceutical formulation of the anti-cell hyperproliferation agent is used in the treatment of cell hyperproliferation.

### Claim 44

A shampoo for administering an anti-dandruff agent to a subject in need thereof, wherein the anti-dandruff agent comprises:
a therapeutically effective amount of a mastic essential oil isolated from the species Pistacia lentiscus var. chia or synthetic equivalent thereof; and
a shampoo base.

### Claim 45 (depends on 44)

A shampoo according to claim 44, wherein the anti-dandruff agent further comprises a mastic whole extract product.

### Claim 46 (depends on 44)

A shampoo according to claim 44, wherein the anti-dandruff agent further comprises a mastic acid extract product.

### Claim 47 (depends on 44)

A shampoo according to claim 44, wherein the anti-dandruff agent further comprises a mastic neutral extract product.

### Claim 48 (depends on 44)

A shampoo according to claim 44, wherein the anti-dandruff agent further comprises a mastic isolated component product.
